Search research articles
Contact Us
Filters
Showing results (21-30 of 61) with videos related to
Page
of 7
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 25, 2009
Why do residents choose the medical oncology specialty? Implications for future recruitment--results of the 2007 French Association of Residents in Oncology (AERIO) Survey
Y Loriot, L Albiges-Sauvin, D Dionysopoulos, et al.
European Journal of Cancer (Oxford, England : 1990)
|
July 15, 2010
Prevalence and causes of burnout amongst oncology residents: a comprehensive nationwide cross-sectional study
P Blanchard, D Truchot, L Albiges-Sauvin, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 12, 2013
Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100)
Y Loriot, D Bianchini, E Ileana, et al.
British Journal of Cancer
|
March 6, 2014
Tumoral CD105 is a novel independent prognostic marker for prognosis in clear-cell renal cell carcinoma
A Saroufim, Y Messai, M Hasmim, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 30, 2012
Benefit of adjuvant trastuzumab-based chemotherapy in T1ab node-negative HER2-overexpressing breast carcinomas: a multicenter retrospective series
M J Rodrigues, J Peron, J-S Frénel, et al.
ESMO Open
|
April 9, 2022
Efficacy and safety of avelumab plus axitinib in elderly patients with advanced renal cell carcinoma: extended follow-up results from JAVELIN Renal 101
Y Tomita, R J Motzer, T K Choueiri, et al.
ESMO Open
|
October 22, 2023
Efficacy of avelumab plus axitinib versus sunitinib by numbers of IMDC risk factors and target tumor sites at baseline in advanced renal cell carcinoma: long-term follow-up results from JAVELIN Renal 101
Y Tomita, R J Motzer, T K Choueiri, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 1, 2017
Phase I/II trial of cabazitaxel plus abiraterone in patients with metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel and abiraterone
C Massard, J Mateo, Y Loriot, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 6, 2020
Tocilizumab, an anti-IL-6 receptor antibody, to treat COVID-19-related respiratory failure: a case report
J-M Michot, L Albiges, N Chaput, et al.
ESMO Real World Data and Digital Oncology
|
February 6, 2026
Real-word evidence in anti-VEGF naive patients treated with pazopanib for metastatic renal cell carcinoma (mRCC), the APOLON Study
P Barthelemy, A Thiery-Vuillemin, T Lebret, et al.
Page
of 7
Search research articles
Search
Showing results (21-30 of 61) with videos related to
Sort By:
Page
of 7
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 25, 2009
Why do residents choose the medical oncology specialty? Implications for future recruitment--results of the 2007 French Association of Residents in Oncology (AERIO) Survey
Y Loriot, L Albiges-Sauvin, D Dionysopoulos, et al.
European Journal of Cancer (Oxford, England : 1990)
|
July 15, 2010
Prevalence and causes of burnout amongst oncology residents: a comprehensive nationwide cross-sectional study
P Blanchard, D Truchot, L Albiges-Sauvin, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 12, 2013
Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100)
Y Loriot, D Bianchini, E Ileana, et al.
British Journal of Cancer
|
March 6, 2014
Tumoral CD105 is a novel independent prognostic marker for prognosis in clear-cell renal cell carcinoma
A Saroufim, Y Messai, M Hasmim, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 30, 2012
Benefit of adjuvant trastuzumab-based chemotherapy in T1ab node-negative HER2-overexpressing breast carcinomas: a multicenter retrospective series
M J Rodrigues, J Peron, J-S Frénel, et al.
ESMO Open
|
April 9, 2022
Efficacy and safety of avelumab plus axitinib in elderly patients with advanced renal cell carcinoma: extended follow-up results from JAVELIN Renal 101
Y Tomita, R J Motzer, T K Choueiri, et al.
ESMO Open
|
October 22, 2023
Efficacy of avelumab plus axitinib versus sunitinib by numbers of IMDC risk factors and target tumor sites at baseline in advanced renal cell carcinoma: long-term follow-up results from JAVELIN Renal 101
Y Tomita, R J Motzer, T K Choueiri, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 1, 2017
Phase I/II trial of cabazitaxel plus abiraterone in patients with metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel and abiraterone
C Massard, J Mateo, Y Loriot, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 6, 2020
Tocilizumab, an anti-IL-6 receptor antibody, to treat COVID-19-related respiratory failure: a case report
J-M Michot, L Albiges, N Chaput, et al.
ESMO Real World Data and Digital Oncology
|
February 6, 2026
Real-word evidence in anti-VEGF naive patients treated with pazopanib for metastatic renal cell carcinoma (mRCC), the APOLON Study
P Barthelemy, A Thiery-Vuillemin, T Lebret, et al.
Page
of 7